Akebia Therapeutics announced that the Swiss Agency for Therapeutic Products has granted marketing authorization for Vafseo, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor for the treatment of symptomatic anemia associated with chronic kidney disease in adults on chronic maintenance dialysis.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on AKBA: